Meet Lachnospiraceae, the Gut Bacteria Tied to Cancer Immunotherapy

If you've ever searched whether gut bacteria affect your immune system after a diagnosis, you've probably run into the name Lachnospiraceae. It's one of the most common bacterial families in the human gut, making up 15% to 25% of the microbiome in most healthy adults, and it keeps surfacing in research on everything from inflammatory bowel disease to how well cancer immunotherapy works. A new critical review in the journal Comprehensive Reviews in Food Science and Food Safety pulls together 143 separate studies to ask a blunt question: how much of that promise actually holds up in people, versus what's still a strong hunch from rodent experiments? The authors' answer is more sobering than the "gut health" hype usually allows, though one member of the family has already cleared a real regulatory hurdle.

Key Takeaways

• Lachnospiraceae, a family of gut bacteria present in most healthy adults, ferments fiber into immune-signaling compounds called short-chain fatty acids, but most of that mechanism is proven in mice, not people.
• In a cohort of 158 patients with melanoma, lung cancer, or kidney cancer, higher levels of one Lachnospiraceae subgroup tracked with more tumor-fighting immune cells in people who responded to checkpoint-inhibitor immunotherapy, a correlation, not proof the bacteria caused the response.
• Only one strain, Anaerobutyricum soehngenii, has FDA "no questions" GRAS status and placebo-controlled human trial data, and that data covers blood sugar control in prediabetes, not cancer or autoimmune disease.
• No completed human trial has tested a defined Lachnospiraceae strain against any immune condition, and strain-level differences mean a result from one species can't be assumed to hold for the rest of the family.

Lachnospiraceae Bacteria Turn Fiber Into Immune Signals

Lachnospiraceae is a family of more than 60 bacterial genera (a genus is a group of closely related species) that live in the colon and specialize in fermenting the dietary fiber the human body can't break down on its own. The byproducts are short-chain fatty acids, chiefly butyrate, propionate, and acetate, and they do more than feed colon cells. In rodent and cell studies, these acids, especially butyrate, block an enzyme called histone deacetylase and activate receptors on immune cells, a combination that pushes the immune system toward more regulatory T cells (the cells that dial inflammation down) and fewer Th17 cells (which drive it up). The review's authors describe butyrate as acting like a global "rheostat" for the immune system in these models. The catch, repeated throughout the review: the doses used in most lab experiments are far higher than what colon tissue actually sees in a person eating a normal diet.

The Cancer Immunotherapy Link Getting the Most Attention

Autoimmune and metabolic disease aren't the only conditions where this family keeps turning up; cancer immunotherapy is where the data are drawing the most attention. The review describes a retrospective cohort of 158 patients with stage III or IV melanoma, non-small-cell lung cancer, or renal cell carcinoma in which people who responded to checkpoint-inhibitor drugs (which unleash the immune system on tumors) had higher fecal levels of a Lachnospiraceae subgroup called Lachnospiraceae_UCG_010, and that level tracked with more CD8+ T cells (the immune cells that directly kill tumor cells) in both blood and tumor tissue. The pattern shows up elsewhere, too: a separate peer-reviewed analysis of the tumor microbiome in metastatic melanoma patients on checkpoint inhibitors (Robinson et al., 2023) reported similar associations between gut bacterial composition and treatment outcome. A microbiome-based prediction tool built on signals like these reportedly flagged likely responders with 78.6% sensitivity in one multicenter cohort. For anyone managing inflammatory bowel disease, rheumatoid arthritis, Type 2 diabetes, or going through cancer immunotherapy, this is the specific reason Lachnospiraceae shows up in health forums: it is one of the few bacterial names with a plausible, mechanistic story tying gut fermentation to how a person's own immune cells behave.

A 143-Study Review, Not One New Experiment

This isn't a single new study; it's a critical narrative review, meaning the authors didn't run a lab experiment, they systematically combed the published literature and graded what it does and doesn't show. Starting from an initial multi-database search, they narrowed 961 title-and-abstract records down to 187 full-text articles, and ultimately included 143 studies in the final synthesis: 82 preclinical (cell or animal) studies, 46 human observational studies, and 15 human interventional trials. That ratio is itself a finding. For roughly every five preclinical or observational papers on Lachnospiraceae, there is only about one trial that actually intervened on a human being, and the review grades the overall quality of that handful of human trials as low to very low for every condition except one.

What's Actually Usable for Readers Right Now

The one bright spot with real human trial data is Anaerobutyricum soehngenii, a Lachnospiraceae strain that in April 2023 became the first, and so far only, member of this bacterial family to receive "no questions" Generally Recognized As Safe status from the FDA, clearing it for use in foods like yogurt and sports drinks. In a placebo-controlled trial of 98 adults with prediabetes, daily supplementation with the strain modestly improved blood-sugar stability and lowered HbA1c (a marker of average blood sugar) by about 1 mmol/mol, alongside a small drop in diastolic blood pressure, building on earlier dose-response pilot data in the same strain. That's real, but narrow. It is evidence for one strain, in metabolic disease, not for cancer, autoimmune conditions, or the family as a whole. Dietary fiber, such as inulin, resistant starch, pectin, and whole-grain arabinoxylan, has each raised Lachnospiraceae abundance modestly in small human trials, and that is the only other lever with human data behind it, though even then the review stops short of crediting Lachnospiraceae specifically for the benefit. There is currently no Lachnospiraceae supplement with evidence to support an immune or cancer-related claim.

The Open Question: Cause, Consequence, or Bystander?

Nearly every human data point in this review is correlational: people with a certain disease, or a certain treatment response, happen to have more or less Lachnospiraceae, but that doesn't establish which came first. Diet, antibiotics, disease stage, and even the dozens of other bacteria that travel alongside Lachnospiraceae in a fecal microbiota transplant all confound the picture, and the review notes that the reported odds ratios linking this bacterial family to immunotherapy response are modest, in the 1.5 to 2.0 range. Strain-level differences complicate things further: while Roseburia and Eubacterium rectale strains look consistently beneficial, Blautia producta, a different genus in the same family, has been linked to rare bloodstream infections in severely immunocompromised patients, so "Lachnospiraceae is good for you" is already too broad a claim within the family itself. Several fecal microbiota transplant trials combined with immunotherapy have reported encouraging response rates, but because a transplant moves an entire bacterial community at once, none of them can credit Lachnospiraceae specifically for any benefit seen.

No Timeline Yet for Clinical or Commercial Use

The review is explicit that it will not offer a prediction for when any of this becomes a treatment or a mainstream supplement, calling such timelines speculative given how much remains undone. The priorities its authors lay out are a defined-strain randomized trial program, which still doesn't exist for immune or cancer applications, strain-level genome sequencing across the family's dozens of genera, and multi-omics studies that pair gut bacteria data with direct measurements of human immune tissue rather than fecal proxies. Regulatory uncertainty adds another layer of delay in the US specifically: the FDA's proposed rule changing how GRAS ingredients get notified is expected to publish for public comment later this year, with a final rule unlikely before 2028 or 2029, a timeline that affects how quickly any new strain beyond A. soehngenii could reach the market even for ordinary food use.

Common Questions

What exactly is Lachnospiraceae? It's a family of more than 60 genera of bacteria that live in the human colon and ferment fiber into short-chain fatty acids; in most healthy adults it makes up 15% to 25% of the total gut microbiome.

Does this mean a Lachnospiraceae probiotic could improve how well cancer immunotherapy works? Not based on current evidence. The link is correlational, drawn from retrospective patient data, and no trial has tested whether adding Lachnospiraceae actually improves immunotherapy response in people.

Is there a Lachnospiraceae supplement I can buy today? One strain, Anaerobutyricum soehngenii, is cleared by the FDA for use in food products and has placebo-controlled trial data, but only for blood sugar management in prediabetes, not for immune or cancer-related use.

Should I eat more fiber because of this research? High-fiber eating, such as whole grains, resistant starch, and pectin-rich fruit, is already recommended for general health and has raised Lachnospiraceae abundance in small trials, but the review stops short of crediting Lachnospiraceae specifically for any resulting benefit.

References

1. Ruijun Wang, Zhiqi Li, Lina Zhang, Yuanming Pan, Zhanbiao He (2026). Lachnospiraceae in the Food–Gut Axis: A Critical Review of Dietary Modulation, Immune Regulation, and Translational Barriers. Comprehensive Reviews in Food Science and Food Safety. https://doi.org/10.1111/1541-4337.70655
2. The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors. NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC10245822/
3. FDA GRAS Notice Response – Anaerobutyricum soehngenii CH106 (GRN No. 1065). fda.gov. https://www.fda.gov/media/177677/download
4. Pim W. Gilijamse, Annick V. Hartstra, Evgeni Levin, et al. (2020). Treatment with Anaerobutyricum soehngenii: a pilot study of safety and dose–response effects on glucose metabolism in human subjects with metabolic syndrome. npj Biofilms and Microbiomes. https://doi.org/10.1038/s41522-020-0127-0
5. Fecal Transplants Help Patients with Advanced Melanoma Respond to Immunotherapy. cancer.gov. https://www.cancer.gov/news-events/press-releases/2021/fecal-transplants-cancer-immunotherapy